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lating health outcomes were reported in two-thirds of the submissions. However, 
worst-case scenarios were hardly presented. Compliance with HAS guidelines for 
exploring methodological uncertainty (e.g. perspective, discounting, time horizon) 
was fair. However, the choice of the comparator(s)–an essential component of a 
CEA–was considered problematic in nearly 40% of submissions. ConClusions: 
Overall, reporting of DSA and PSA is complying with HAS guidelines. More work is 
needed to explore uncertainty, in particular, to account for correlations between 
model input parameters and to enhance the analysis of structural uncertainty.
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objeCtives: Since 2011 the early benefit assessment (EBA) is mandatory to obtain 
reimbursement for new drugs in Germany. By law EBA of the G-BA (Federal Joint 
Committee) can be conditional for a certain period of time. This study explores 
the number, duration and rationale of conditional G-BA resolutions. Furthermore 
the provided, later given (during statement process), accepted and additionally 
requested study data is analysed in this context. Methods: AMNOG dossiers and 
resolutions of the G-BA including justifications until June 2014 were reviewed for rel-
evant information and analysed with special regard to the submitted and accepted 
study data. Drugs which were directly allocated to a fixed-reference price group 
were excluded. Results: 22 new drugs with conditional resolutions were identified 
(29.3% of all resolutions; 2012: 6, 2013: 10, 2014: 6). Duration varied between 1 and 5 
years (1: 4, 2: 8, 3: 5, 4: 1, 5: 4). Conditional resolutions were most common in cancer 
(n= 13; 59.1%) drugs. 91.0% had at least a benefit (none: 2, minor: 12, considerable: 
6, not quantifiable: 2) in one subgroup. G-BA limited resolutions due to (a) no suf-
ficient data to assess the benefit (n= 9), (b) conditional approval and/or further data 
requests by EMA (European Medicines Agency) (n= 6), (c) expected new study results 
(n= 6), and (d) due to a formal incorrect dossier (n= 1). To date, only vemurafenib 
was assessed again with same result as before. ConClusions: From 2011 on an 
increased number of resolutions and especially cancer drugs were conditional. Only 
in a few cases G-BA defined in the resolution which specific data has to be shown 
in the re-assessment. In these cases the requirements concerning further evidence 
were not part of the G-BA voting. As currently just one drug was re-assessed, no 
conclusions can be drawn how re-assessment changes the extent or certainty of 
additional benefit.
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objeCtives: Gemeinsame Bundesausschuss (G-BA) assesses the additional 
benefit of newly-approved drugs compared to the G-BA-determined appropriate 
comparator. As part of the submission, manufacturers provide annual drug cost 
estimates. This research tests whether manufacturers submit higher annual costs 
for drugs that provide greater additional benefit, that is, whether added benefit is 
priced. Methods: The influence of G-BA’s additional benefit assessment on the 
manufacturer’s estimated per patient annual drug cost was estimated via ordinary 
least squares based on 73 reviews. The model also included controls for the (log) 
size of the target population and the annual cost of the comparator. These vari-
ables were collected from the Federal Gazette publication or the “Beschluss” docu-
ment. Results: Our model explains three-quarters of the variation in annual drug 
cost (R2= .76). Conditional on the target population and the cost of its comparator, 
a drug assessed as having unquantifiable or minor added benefit is estimated to 
have a per patient annual cost about 2 times greater than one with no added benefit 
(p= .02). A drug with the highest assessment, “Considerable additional benefit,” is 
estimated to have an annual per patient cost that is 9 times greater (p< .01). There 
is evidence of a “quantity discount”: doubling the size of the target population is 
estimated to reduce the per-patient annual cost by 18% (p< .01). ConClusions: 
If, as seems plausible, manufacturers’ assessments of their own drugs are aligned 
with G-BA’s assessments, our results are consistent with manufacturers setting 
higher prices for more beneficial drugs. The price a manufacturer uses to estimate 
annual cost represents in effect a proposed allocation of its drug’s benefits between 
itself and patients/payers. This research raises at least two important questions: 
How do manufacturers propose to share the gains and what sharing emerges from 
subsequent price negotiations?
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objeCtives: The objective of our research is to give first an overview of the risks 
of bias in trial-based economic evaluation, and second to identify how key sources 
for bias can be revealed and overcome (bias-reducing strategies) in future trial-
based economic evaluation in the fields of general practice and health psychol-
ogy. Methods: A scoping review was performed using PubMed and the NHS 
Economic Evaluation data base. It was complemented with experiences of the 
authors. Sources of bias in trial-based economic evaluation as well as bias-reduc-
ing strategies are discussed. Results: The different forms of bias are presented, 
and assigned to a particular trial phase. A distinction is made between pre-trial 
biases, biases during the trial and biases that are relevant after the actual trial. All 
potential forms of bias are discussed in detail and strategies are shown to detect 
and overcome these biases. ConClusions: In order to avoid bias in trial-based 
economic evaluations, one has to be aware of all of the possible forms of bias and 
all stakeholders have to examine trial-based economic evaluations in a rigorous 
and stringent manner. Our research findings can be helpful in this examination 
as they provide an overview of the possible biases which researchers should take 
into account.
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objeCtives: In May 2010 the UK government set out its intentions to reform the 
current method of pricing branded medicines and introduced a new system of 
value-based pricing (VBP). This was to replace the Pharmaceutical Price Regulation 
Scheme (PPRS) which expired at the end of 2013. With discussion still ongoing, 
and the PPRS renewed up until end of 2018, it has been indicated that VBP will no 
longer relate to medicines’ pricing, but instead will be a reshaping of the Health 
Technology Assessment (HTA) model employed by the UK in its appraisal of new 
medicines, and renamed Value Based Assessment (VBA). As medicine assessment 
is devolved in the UK, performed by NICE in England and the SMC in Scotland, 
we seek to understand whether the SMC will adopt the same approach to VBA as 
NICE. Methods: The research was conducted through in-depth secondary research 
and interviews with stakeholders, including payers and KOLs, in UK. Results: Both 
NICE and the SMC have indicated they will continue to use QALY as a measurement 
of clinical and cost effectiveness while also incorporating issues such as burden 
of illness and wider societal impact in their assessment. However, their approach 
to conducting such assessments may differ with the SMC suggesting using a new 
system of patient and clinician engagement (PACE), currently in use for the appraisal 
of medicines for end of life or rare conditions (orphans), as a wider process to 
determine Scotland’s requirement for a value based approach to assess all new 
medicines. ConClusions: Manufacturers would be encouraged to closely follow 
the outcomes from the new PACE system, incorporated into the SMC assessment 
for end of life and orphan therapies, to ensure readiness for the introduction of 
VBA in Scotland.
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objeCtives: The current study seeks to assess discrepancies between national 
inpatient drug recommendations issued through the cost-effectiveness pilot project 
(Klinikläkemedelsprojektet) in Sweden and local uptake reflected by Stockholm 
Country Council´s (SLL) procurement activity. Methods: Secondary research 
investigated the 15 inpatient drug recommendations issued by the national New 
Pharmaceutical Therapies group (Nya Lakemedels Terapier, NLT) in 2013 and com-
pared these against the SLL’s 2014 procurement list. Results: In 2013, the NLT 
group issued a total of 15 recommendations for products in a variety of therapeu-
tic areas (TA). Out of these, ten gained positive national decisions, 50% of which 
were for oncology drugs. Of those recommended, cancer drug pertuzumab (Perjeta; 
Roche, Switzerland) saw the highest incremental cost-effectiveness ratio (ICER), at 
SEK2,565,000 (USD383,730) per quality-adjusted life year (QALY) - greatly exceed-
ing the informal cost-effectiveness threshold of SEK800,000 in Sweden. There was 
a significant discrepancy in the number of nationally recommended drugs (ten) 
in 2013, versus the SLL uptake (two) by 2014. The two recommended products 
subsequently procured were Roche´s (Switzerland) ophthalmology drug ranibi-
zumab (Lucentis) and Takeda´s (Japan) oncology therapy brentuximab vedotin 
(Adcetris). ConClusions: The Swedish government is contemplating making the 
Klinikläkemedelsprojektet permanent, and as such the alignment between national 
and local level priorities is a critical component of its integrity. The results show 
that eight nationally recommended products had not been procured, indicating 
that there is still a discrepancy between those recommendations and uptake at 
the local level, based on the current data. One explanation for the discrepancy 
could be attributed to the funding system, where local payers are responsible for 
funding inpatient drugs.
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objeCtives: Veneto leads the nation in terms of better health status and phar-
maceutical expenditures within budget. This study aimed to assess the region’s 
Health Technology Assessment (HTA) approach (structure, methods, and process 
of conducting HTA) by observing Evaluation of Pharmaceutical Effectiveness Unit’s 
(UVEF) evaluations on drugs, the concomitant Regional Technical Commission 
(CTR) decisions on formulary inclusion, and the evidences considered. Methods: 
We reviewed all HTA reports in the UVEF website evaluating the HTA dimensions 
assessed, if they were in line with the HTA scoping document by the Regional 
Decrees (2008), and changes over time. Further, this research evaluated the presence 
of explicit explanations behind each CTR decision. Results: 223 HTA listings were 
retrieved in the UVEF website (2004-2011). 50.23% were published before the actual 
establishment of UVEF (2008) and were probably labelled HTA retrospectively. Fewer 
dimensions were assessed in the earlier documents and the most extensive changes 
were seen in 2008. The most assessed dimensions were Efficacy, Safety, and Costs 
and the least assessed were Budget Impact Analysis, Target Population, Place in 
therapy, and Assessment of Innovation. The Regional Decrees (2008) were impactful 
on the structure of the HTA reports, however these are still not fully compliant to 
the scoping document. A total of 72 CTR decisions were found in the website from 
2009 to 2011. On average, 92% of all CTR documents have a documented explana-
tion behind each decision. ConClusions: The HTA approach in Veneto is evolving 
towards the development of uniformity in the documents and a single transparent 
approach. The upward trend of attaching CTR decisions with explicit explanations 
